Tozhu single resistance china has been approved for the treatment of car-T therapy caused by cytokine storms.

Recently, Roche's toad monoantigen injection (trade name: Jaromero) was approved by the State Drug Administration for severe or life-threatening cytokine release syndrome (CRS) caused by chisellular antigens (CAR) T cells in adult and children 2 years of age and older.
is also the third indication it has been approved in China, after Ameero was approved for rheumatoid arthritis (RA) and systemic young idlytic arthritis (sJIA) in 2013 and 2016, respectively.
August 2019, Jamero was included in the National Health Insurance Directory for systemic secondary treatment of early childhood idiotic arthritis, as well as for patients with a reduced activity of less than 50% in patients with a well-diagnosed RA-by-traditional DMARD treatment for 3 to 6 months.
It is understood that during the treatment of CAR-T cells, cytokine release syndrome (CRS), neurotoxicity, tumor dissolution syndrome, blood cell reduction/infection, low immunoglobulinemia and hepatitis B virus activation and other adverse reactions, of which CRS is one of the most frequent and prominent acute toxic reactions, research data show that up to 70% of patients will have severe cytokine release syndrome.
The approval of this free clinical trial for the treatment of CRS allergy is based on the clinical trial data of CAR-T cell therapy for blood system diseases provided by two CAR-T companies worldwide, which effectively evaluates the efficacy of toad monotherapy CRS.
At present, in China, there are a number of enterprises in the development of tozhu single anti-biosynthic drugs, according to the pharmaceutical Rubik's Cube PharmaGO database, including Baiotai, Haizheng Pharmaceuticals, Hengrui Pharmaceuticals, Tagg Pharmaceuticals, Yanxin Bio, Jinyu Biology, Maybotenko Pharmaceuticals, etc., the development progress from the first phase of clinical trials and phase iii clinical trials.
May of this year, CDE issued guidelines for clinical trials of toads of biosynthic drugs (draft for comments) to better promote the development of biosynthic drugs for the product.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.